Literature DB >> 12105998

Psychostimulant use in the rehabilitation of individuals with traumatic brain injury.

John Whyte1, Monica Vaccaro, Patricia Grieb-Neff, Tessa Hart.   

Abstract

BACKGROUND: Psychostimulants are used commonly in the rehabilitation of individuals with traumatic brain injury (TBI), despite the dearth of well-controlled studies of their effects. The available literature suggests that these drugs predominantly affect the speed of cognitive processing and certain observational ratings of mood and behavior. Effects on sustained attention, distractibility, and memory are less clear.
OBJECTIVE: This article reviews the controlled research literature on the use of these drugs in TBI and presents preliminary data from the authors' laboratory that extends these findings. Some of the common research pitfalls that have limited progress in research on these drugs are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12105998     DOI: 10.1097/00001199-200208000-00003

Source DB:  PubMed          Journal:  J Head Trauma Rehabil        ISSN: 0885-9701            Impact factor:   2.710


  14 in total

1.  Treating head injuries. Outcomes in specialist units using protocols may not be better.

Authors:  Vincenzo Bonicalzi; Sergio Canavero
Journal:  BMJ       Date:  2002-12-14

Review 2.  Interventions for attention problems after pediatric traumatic brain injury: what is the evidence?

Authors:  Barynia Backeljauw; Brad G Kurowski
Journal:  PM R       Date:  2014-04-19       Impact factor: 2.298

3.  Methylphenidate and Memory and Attention Adaptation Training for Persistent Cognitive Symptoms after Traumatic Brain Injury: A Randomized, Placebo-Controlled Trial.

Authors:  Brenna C McDonald; Laura A Flashman; David B Arciniegas; Robert J Ferguson; Li Xing; Jaroslaw Harezlak; Gwen C Sprehn; Flora M Hammond; Arthur C Maerlender; Carrie L Kruck; Karen L Gillock; Kim Frey; Rachel N Wall; Andrew J Saykin; Thomas W McAllister
Journal:  Neuropsychopharmacology       Date:  2016-11-22       Impact factor: 7.853

4.  Decreased serum glucose levels after initiation of methylphenidate in a patient status post-cerebellar tumour resection: a potential interaction with glipizide.

Authors:  Samuel T Gontkovsky; Robert Nevels; Nicholas B McDonald; Michael H Winkelmann
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

5.  Amantadine for adynamic speech: possible benefit for aphasia?

Authors:  Anna M Barrett; Paul J Eslinger
Journal:  Am J Phys Med Rehabil       Date:  2007-08       Impact factor: 2.159

Review 6.  Polymorphisms in genes modulating the dopamine system: do they inf luence outcome and response to medication after traumatic brain injury?

Authors:  Thomas W McAllister
Journal:  J Head Trauma Rehabil       Date:  2009 Jan-Feb       Impact factor: 2.710

7.  Prescribing multiple neurostimulants during rehabilitation for severe brain injury.

Authors:  Amy A Herrold; Theresa Louise-Bender Pape; Ann Guernon; Trudy Mallinson; Eileen Collins; Neil Jordan
Journal:  ScientificWorldJournal       Date:  2014-12-22

Review 8.  Methylphenidate on Cognitive Improvement in Patients with Traumatic Brain Injury: A Meta-Analysis.

Authors:  Chi-Hsien Huang; Chia-Chen Huang; Cheuk-Kwan Sun; Gong-Hong Lin; Wen-Hsuan Hou
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

Review 9.  Selective Serotonin Reuptake Inhibitors for Treating Neurocognitive and Neuropsychiatric Disorders Following Traumatic Brain Injury: An Evaluation of Current Evidence.

Authors:  John K Yue; John F Burke; Pavan S Upadhyayula; Ethan A Winkler; Hansen Deng; Caitlin K Robinson; Romain Pirracchio; Catherine G Suen; Sourabh Sharma; Adam R Ferguson; Laura B Ngwenya; Murray B Stein; Geoffrey T Manley; Phiroz E Tarapore
Journal:  Brain Sci       Date:  2017-07-25

10.  Efficacy of methylphenidate for the treatment of mental sequelae after traumatic brain injury.

Authors:  Wei-Tao Zhang; Ya-Fei Wang
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.